glp-1 masld Incretin-based therapies in MASLD/MASH: from receptor agonists to dual and triple agonists Effect of pemvidutide, a GLP-1/glucagon

To view or add a comment, sign in 13,889 followers

It may help explain why researchers are interested in retatrutide, but it does not prove that it is the better choice for a specific person

A vicious cycle unfolds from there: Carrying more weight may pump up the size of your fat cells and trigger inflammation, both of which can make it even tougher for your cells to respond to insulin

Mechanism of action: GLP-1 receptor agonists bind to GLP-1 receptors located throughout the body, particularly in pancreatic beta cells, the gastrointestinal tract, and the central nervous system

Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective

Dose schedule modifications for specific goals While the standard schedule targets 12mg maintenance, not every researcher aims for the same outcome